...ve opened pathways for developing targeted therapies that address specific genetic abnormalities in mesothelioma cells. Under Dr. Bueno's direction, the IMP c
...ld on the success of the CheckMate 743 trial while addressing the specific genetic vulnerabilities identified through genomic profiling.<ref name="pubmed_3348
...
24 KB (3,109 words) - 19:06, 20 May 2026
|title=Mesothelioma Molecular and Genetic Testing: BAP1, CDKN2A, NGS Panels & Biomarker-Guided Treatment
|description=Comprehensive guide to molecular and genetic testing for mesothelioma including BAP1 mutations, CDKN2A FISH, NF2 inactivation, n
...
55 KB (7,216 words) - 23:25, 14 May 2026
...ts, fiber types, pleural vs peritoneal differences, biological mechanisms, genetic predisposition (BAP1/RAD51), and courtroom implications for statute of limi
| style="padding:10px; border:1px solid #1a5276;" | '''8.5 years (with genetic predisposition)'''<ref name="shortlatencypmc" />
...
53 KB (7,021 words) - 23:25, 14 May 2026
...dian 5 years compared to less than 1 year for non-carriers, making genetic testing critical
...hereditary cancer syndrome. Clinical practice guidelines (2023) recommend genetic counseling and surveillance for carriers, including regular imaging for mes
...
45 KB (5,643 words) - 23:25, 14 May 2026
* Gene therapy introduces specific genetic material into cells using viral or non-viral vectors to kill tumor cells, r
...rapidly dividing cells indiscriminately, gene therapy introduces specific genetic material into cells to kill tumor cells, restore lost tumor suppressor func
...
67 KB (8,772 words) - 23:06, 14 May 2026
| style="padding:8px 10px; background:#f8f9fa; font-weight:bold;" | Germline testing
| style="padding:8px 10px;" | BAP1 germline testing — ASCO 2025 Strong Recommendation for all patients
...
39 KB (4,780 words) - 23:07, 14 May 2026
...logical subtypes, TNM 8th edition staging, blood biomarkers, and molecular testing.
...ing" /> Emerging molecular testing for '''BAP1''', '''CDKN2A''', and other genetic alterations is increasingly important for both diagnosis and treatment plan
...
58 KB (7,639 words) - 23:25, 14 May 2026
...ighlighting the role of non-asbestos causes—including erionite, radiation, genetic predisposition (BAP1 mutations), carbon nanotubes, and spontaneous mesothel
...lowing damaged mesothelial cells to survive and replicate despite carrying genetic mutations. HMGB1 protein release drives inflammasome activation.
...
42 KB (5,304 words) - 23:25, 14 May 2026
...-style:italic; border-bottom:1px solid #dee2e6;" | Prediagnostic Biomarker Testing for Mesothelioma
...re diagnosis, providing the prospective evidence base needed to move panel testing toward clinical surveillance programs.<ref name="bmjopen_diaphragm" /><ref
...
39 KB (5,126 words) - 23:25, 14 May 2026
...ns''' — patients seen by listed specialists gain access to 6 active trials testing CAR T-cell therapy, neoadjuvant immunotherapy, and gene therapy unavailable
...stigator of the NEMO trial, a randomized phase II study at Baylor and Duke testing chemotherapy plus immunotherapy before surgery versus immunotherapy alone b
...
61 KB (8,018 words) - 23:25, 14 May 2026
...mmation. This multiplex approach far outperformed single-marker mesothelin testing (AUC 0.82, sensitivity 66%, specificity 88%) in the same populations. The D
== What Is the Future of Mesothelioma Blood Testing? ==
...
38 KB (4,854 words) - 23:25, 14 May 2026
| style="padding:10px;" | '''ASCO 2025 Universal Germline Testing'''
...ding:10px;" | All mesothelioma patients should be offered germline genetic testing (ASCO Recommendation 7.1, Strong); BAP1 carriers survive ~5x longer and may
...
62 KB (7,842 words) - 23:25, 14 May 2026
...erapy that blocks proteins driving cancer growth in patients with specific genetic mutations.
* '''Genetic Counseling:''' For patients and families concerned about hereditary cancer
...
29 KB (3,638 words) - 23:25, 14 May 2026
* '''Biomarker testing identifies 13-fold survival differences''' — Patients with undetectable ctD
* '''BAP1 mutation paradox''' — Patients with this genetic alteration survive 5x longer (5 years vs. under 1 year) despite having a tu
...
37 KB (4,496 words) - 23:26, 14 May 2026
...emistry''' with standardized marker panels, conducting ancillary molecular testing including '''BAP1 loss''' and '''CDKN2A FISH''', and developing an evidence
...ioma from benign mesothelial proliferations when combined with CDKN2A FISH testing
...
60 KB (7,904 words) - 23:25, 14 May 2026
...part of the initial IHC panel. Additionally, BAP1 loss and CDKN2A deletion testing are increasingly important for distinguishing malignant mesothelioma from w
...her risk factors — including chronic hydrocele, inflammation, and possibly genetic predisposition — may also play roles.<ref name="marinaccio" /><ref name="vi
...
50 KB (6,428 words) - 23:26, 14 May 2026
...ncologist or thoracic-oncology multidisciplinary team. Methylation subtype testing is investigational and is not standard of care for mesothelioma treatment s
As of May 2026, DNA methylation subtype testing is '''not standard of care''' for pleural mesothelioma treatment selection
...
36 KB (4,576 words) - 21:55, 25 May 2026
...es the best mesothelioma treatment options based on a patient's individual genetic characteristics.<ref name="dandell_compensation" />
* '''Personalized Medicine:''' Molecular testing to guide treatment decisions is now routine
...
28 KB (3,564 words) - 23:25, 14 May 2026
...incomplete. If the pathology report lists fewer stains, request additional testing before treatment planning.<ref name="pmc_luca_2025" />
* [[Mesothelioma_Molecular_and_Genetic_Testing|Molecular and Genetic Testing]]
...
39 KB (5,219 words) - 23:25, 14 May 2026
...se relationships, and — where relevant — fiber burden analysis and genetic testing evidence.<ref name="dandell6" /><ref name="mesatty2" />
...
32 KB (3,931 words) - 23:26, 14 May 2026
